Additional Clinical Benefit of Agomelatine Treatment for Major Depressive Disorder in Naturalistic Treatment Setting

Kyung Ho Lee; Tae Sun Han; Changsu Han; Won-Myong Bahk; Soo-Jung Lee; Ashwin A Patkar; Prakash S Masand; Chi-Un Pae

doi:10.9758/cpn.23.1060

Additional Clinical Benefit of Agomelatine Treatment for Major Depressive Disorder in Naturalistic Treatment Setting

Clin Psychopharmacol Neurosci. 2023 Aug 31;21(3):594-598. doi: 10.9758/cpn.23.1060.

Authors

Kyung Ho Lee^{1

2}, Tae Sun Han³, Changsu Han⁴, Won-Myong Bahk³, Soo-Jung Lee³, Ashwin A Patkar⁵, Prakash S Masand⁶, Chi-Un Pae^{2

3}

Affiliations

¹ Departments of Dermatology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
² Cell Death Disease Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
³ Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea.
⁴ Department of Psychiatry, Korea University College of Medicine, Seoul, Korea.
⁵ Department of Psychiatry and Behavioral Sciences, Rush University Medical Center, Chicago, IL, USA.
⁶ Duke-NUS Medical School, Singapore.

Abstract

Objective: This study tried to observe additional benefit of agomelatine (AGO) treatment for major depressive disorder (MDD) in routine practice.

Methods: Retrospective chart review (n = 63) was conducted for additional benefit of combination with or switching to AGO in MDD patients without full remission. The primary endpoint was the mean change of Clinical Global Impression-Clinical Benefit (CGI-CB) total scores from baseline to the endpoint. Additional secondary endpoints were also collected.

Results: The changes of CGI-CB (Z = -3.073, p = 0.002) and Montgomery-Åsberg Depression Rating Scale (Z = -3.483, p < 0.001) total scores were significantly decreased from baseline to the endpoint, respectively. At the endpoint, the remission rate was 22.6% (n = 18) and 28.6% of patient had improvement in CGI-CB total scores at the endpoint. No significant adverse events were observed.

Conclusion: This study has shown additional benefit of AGO treatment as combination or switching agent for MDD patients without full remission in routine practice. However, adequately-powered and well-controlled studies are necessary for generalization of the present findings.

Keywords: Agomelatine; Clinical benefit; Depression; Pharmacotherapy.

Grants and funding

Funding This study was supported by Whan In Pharm. Co., Ltd, Seoul, Korea; the funding sources had no role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.